Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat in Pediatric INI1-Negative Tumors or Synovial Sarcoma
NCT02601937Phase 1Completed
- Sponsor
- Epizyme, Inc.
- Start
- Jan 2016
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 1, open-label trial of tazemetostat in malignant rhabdoid tumor (MRT), Atypical teratoid rhabdoid tumor (ATRT), malignant rhabdoid tumor of the kidney (MRTK) and 7 more (11 arms), sponsored by Epizyme, Inc. Primary endpoints: Recommended Phase 2 Dose at 28 days, Dose-limiting Toxicities at 28 days and 1 more. Started Jan 2016; status: completed.
02
Drugs
tazemetostat
03
Conditions
malignant rhabdoid tumor (MRT)Atypical teratoid rhabdoid tumor (ATRT)malignant rhabdoid tumor of the kidney (MRTK)epithelioid sarcoma (ES)malignant peripheral nerve sheath tumor (MPNST)
Beyond the preview
Go deeper on NCT02601937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02601937.